Europe Smoking Cessation Aids Market

Market Introduction

Smoking cessation lowers the risk of cancer and other serious health problems. Some products contain nicotine as an active ingredient and others do not. Counseling, behavior therapy, medicines, and nicotine-containing products, such as nicotine patches, gum, lozenges, inhalers, and nasal sprays, may be used to help a person quit smoking. They are regulated through the FDA’s Center for Drug Evaluation and Research, which ensures that the products are safe and effective and that their benefits outweigh any known associated risks.

Europe Smoking Cessation Aids Strategic Insights

Strategic insights for the Europe Smoking Cessation Aids provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Smoking Cessation Aids Report Scope

Europe Smoking Cessation Aids Regional Insights

The geographic scope of the Europe Smoking Cessation Aids refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

The Europe smoking cessation aids market is expected to reach US$ 18,639.80 million by 2028 from US$ 7,089.48 million in 2021; it is estimated to grow at a CAGR of 14.8% from 2021 to 2028. Key factors that are driving the growth of this market are increasing number of campaigns to reduce smoking and tobacco dependence and introduction of new smoking cessation aids across the world. However, steeping costs for development of nicotine replacement therapies are likely to restrain the market growth in the future years to some extent.

The government and nongovernment organizations worldwide are coming forward and launching campaigns to provide awareness and undertake measures to curb the diseases caused due to smoking and tobacco consumption. The measures are taken to reduce the economic and health burden caused due to cigarette smoking in countries worldwide. For instance, every year on May 31st, the WHO along with its global partners celebrate World No Tobacco Day (WNTD) to spread education and awareness regarding the harmful and deadly effects of tobacco and second-hand smoke exposure. Initiatives undertaken on this day mainly aim to discourage the consumption of tobacco in any form and educate people regarding the availability of aids that assist in smoking cessation. The launch of anti-smoking campaigns is organized on global, national, and regional levels worldwide.  The governments of various countries have increased excise duties and taxes on tobacco-based cigarettes and cigars to reduce its affordability and thus consumption among common populace. In addition, numerous governments have legalized the use of e-cigarettes as a smoking cessation aid under licensed sales channels to prevent people from opting conventional cigarettes. Thus, the increasing efforts undertaken by governments as well as non-profit and nongovernment organizations to promote the use of smoking cessation aids and reduce the number of smoking populations boost the market growth. The substance and tobacco abuse treatment industry are getting competitive every consecutive year with the introduction of new and innovative therapies by the market players for smoking cessation aids. In addition, medical devices such as nicotine-free e-cigarettes and vapes are being launched by market players at local and regional levels. Thus, the consistent launch of new and innovative smoking cessation aids would become a prevalent trend in the smoking cessation aids market in the coming years.

The Europe region is highly affected due to the outbreak of the COVID-19 pandemic. As per the WHO, they have been evaluating new research constantly, and the new research states that there is positive relation between tobacco and nicotine use, helping COVID-19 patients to get well. For increasing risk for COVID-19, smoking is the major cause of underlying health conditions. However, there is currently insufficient information to confirm any link between tobacco or nicotine in the prevention or treatment of COVID-19. Hence, the impact of the COVID-19 pandemic on smoking cessation aids market is low in Europe region.

Key Market Segments

Based on product, the Europe smoking cessation aids market is segmented into nicotine replacement therapy, drugs, electronic cigarettes, and others. In 2021, the electronic cigarettes segment is likely to hold the largest share of the market and is expected to grow at the fastest rate in the coming years.

Based on end user, the Europe smoking cessation aids market is segmented into hospital pharmacies, online channel, retail pharmacies, and other end users. The retail pharmacies segment is likely to hold the largest share of the market in 2021, whereas the online channel segment is anticipated to register the highest CAGR of the market during the forecast period.

Major Sources and Companies Listed

A few of the primary and secondary sources associated with this report on the Europe smoking cessation aids market are the French National Institute for Prevention and Health Education (INPES), European Federation of Pharmaceutical Industries and Associations (EFPIA), and British Columbia Naturopathic Association (BCNA).

Reasons to buy the report

• Determine prospective investment areas based on a detailed trend analysis of Europe smoking cessation aids market over the next years.
• Gain an in-depth understanding of the underlying factors driving demand for different addictions therapeutics segments in the top spending countries and identify the opportunities offered by each of them.
• Strengthen your knowledge of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
• Identify the major channels driving the Europe smoking cessation aids market, providing a clear picture of future opportunities that will help analyze, resulting in revenue expansion.
• Channelize resources by focusing on the ongoing programs undertaken by the different countries within the Europe smoking cessation aids market.

EUROPE SMOKING CESSATION AIDS MARKET SEGMENTATION

By Product

• Nicotine Replacement Therapy
• Drugs
• Electronic Cigarettes
• Others

By End User

• Hospital Pharmacies
• Online Channel
• Retail Pharmacies
• Other End Users

By Country

• UK
• Germany
• France
• Italy
• Spain
• Rest of Europe

Company Profiles

• Pfizer Inc.
• GlaxoSmithKline plc.
• Dr. Reddy's Laboratories
• Johnson and Johnson Services, Inc.
• Cipla Inc.
• Perrigo Company plc
• Bausch Health Companies Inc.
• Glenmark